Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05751837 · ClinicalTrials.gov registry record · Phase 1

Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal

A Phase 1 study of Malignancy and Abdominal Cancer, sponsored by Patrick Wagner, MD, FACS.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
2
Study locations

NCT05751837 is a Phase 1 study of Malignancy and Abdominal Cancer that has completed, run by Patrick Wagner, MD, FACS. The registered enrollment target is 10 participants, below the 12,586-participant average among 8 other Malignancy trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05751837, a Phase 1 study of Malignancy and Abdominal Cancer, has completed, sponsored by Patrick Wagner, MD, FACS.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this research study is to determine whether a sterile bacteria wall chemical, called lipopolysaccharide (LPS), can be injected safely into abdominal tumors during routine laparoscopic surgery performed as a preliminary procedure in patients who will subsequently undergo a larger planned operation to remove abdominal tumors. The researchers will biopsy the tumor before injection and then again at the time of the larger operation to assess whether any effect of the treatment can be measured.

Interventions

  • BIOLOGICAL Lipopolysaccharide

Study Locations (2)

Pennsylvania

  • Allegheny Health Network Allegheny General Hospital - Pittsburgh
  • Allegheny Health Network West Penn Hospital - Pittsburgh

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2023-03-16
Est. Completion 2024-05-30
Phase Phase 1

Sponsor

Patrick Wagner, MD, FACS

2 total trials

What the Registry Record Tells You About NCT05751837

The ClinicalTrials.gov registry entry for NCT05751837 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,586-participant average among 8 other Malignancy trials with a reported enrollment target (100% lower). The listed sponsor is Patrick Wagner, MD, FACS, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Lipopolysaccharide is the first listed.

NCT05751837 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05751837 about?

NCT05751837 is a clinical study titled "Feasibility Study of Intra-Tumoral Lipopolysaccharide Immunotherapy for Intra-Abdominal". The purpose of this research study is to determine whether a sterile bacteria wall chemical, called lipopolysaccharide (LPS), can be injected safely into abdominal tumors during routine laparoscopic surgery performed as a preliminary procedure in patients who will subsequently undergo a larger plann...

What is the current status of trial NCT05751837?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-03-16. Estimated completion is 2024-05-30.

What conditions does trial NCT05751837 study?

This clinical trial studies the following conditions: Malignancy, Abdominal Cancer.

What interventions are being tested in trial NCT05751837?

The interventions under investigation include: Lipopolysaccharide (BIOLOGICAL).

Who is sponsoring clinical trial NCT05751837?

This trial is sponsored by Patrick Wagner, MD, FACS, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05751837 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.